

Driving T1D Breakthroughs

As the leading global type 1 diabetes (T1D) research and advocacy organization, Breakthrough T1D helps make everyday life with T1D better while driving toward cures. We do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition.

FY24 Mission Progress

Curing T1D is our north star. Until we have cures, we help people with T1D live healthier lives. And in the past year, we have seen incredible progress.



There are now **20+ total devices approved by the FDA**, including the first tubeless AP system; other improved technologies such as the first FDA-approved algorithm for interoperability; and advanced insulins and drugs that work alongside insulin are helping to reduce dangerous highs and lows.



Cell Therapies are in human clinical trials and so far, are yielding outstanding results. Multiple people have been able to stop taking insulin entirely. One therapy has advanced to a phase III clinical trial and will reportedly be submitted for FDA approval next year. Breakthrough T1D's Project ACT will build on this momentum to deliver cell therapies to market, faster.



Tzield™ (teplizumab-mzwv), a drug shown to delay onset of T1D for up to 3 years, is now the first FDA-approved disease-modifying therapy for T1D. Additional research shows that it helps preserve and protect beta cell health and function in people with new onset T1D. Several other disease-modifying therapies for T1D are in different stages of the research and development pipeline.



We have a diversified, **global research strategy** involving different kinds of cures and life-changing breakthroughs—all with multiple projects underway.


Leverage Leads the Way

A global leader in the pursuit of insulin therapy independence for people living with diabetes, Breakthrough T1D accelerates the path to cures by raising funds and allocating them to T1D research and therapy development, and by leveraging our expertise and leadership to bring in additional funding and supporters. This leverage is a key part of our strategy to accelerate cures and life-changing breakthroughs. It has empowered us to grow global support of and investment in T1D research.

In FY24 we saw:

\$521M

Total research support



Breakthrough T1D drew \$375M in additional funding and investments for T1D research

Breakthrough T1D invested \$146M in research in FY24, and through our influence within the public and private sectors, we helped raise another \$375M.

A total of \$521 million—through funding from other organizations, corporations, and governments, in addition to Breakthrough T1D—for T1D research and therapy development.


Of that \$521M, the T1D Fund—Breakthrough T1D's venture philanthropy fund established to drive private investment in T1D therapy research and development—catalyzed \$171M* in private investment in companies developing T1D treatments.

*Calculated using figures as of November 2024.

More than \$1.2 Billion to Cures and Improving Lives

During the past five fiscal years, through our research grants and T1D Fund investments* (those that we have made, as well as private, alongside investments), **more than \$1.2 billion** has been directed to cure T1D and improve lives—with most of it (approximately 82%) focused on cures.

Breakthrough T1D Grants and T1D Fund Investments: FY20 through FY24




*This is committed capital and includes tranchéd financings that may not have had capital deployed yet.

FY24 Breakthrough T1D Revenue


We have four main revenue streams: Events (Walk, Ride, Gala, etc.); Contributions (gifts, etc.); Investment Gains/Losses (T1D Fund and other investments), and International Affiliates/Other (funding raised by our five International Affiliates, other sources).

For FY24, we saw a 16% increase in our total revenue over that of FY23.



FY24 Mission Spend

In FY24 we spent 7% more on advancing our mission than we did in FY23. This includes a 5.5% spending increase over FY23 for research funding and investments (grants, support, advocacy, and new T1D Fund investment), and a 12% spending increase over FY23 in public education/community engagement.



T1D Fund

A Breakthrough T1D Venture™

Founded in 2016, The T1D Fund is a wholly owned subsidiary of Breakthrough T1D that is run on a unique evergreen model: donor funded to support investments in for-profit entities, with exit proceeds recycled back into the Fund.

The T1D Fund is the largest disease-focused venture impact fund with ~\$200M+ in assets under management and ~\$125M of liquid capital to support legacy and new investments. To date, the T1D Fund has an active company portfolio of ~30 companies with a mix of T1D-focused and multi-indication/platform companies across the prevention, treatment, and cures spectrum.

Since its launch, the T1D Fund has made 44 investments with multiple successful company exits ranging from trade sales to big pharma (Semma Therapeutics, Pandion Therapeutics, Inversago Pharma, and Protomer Technologies) to IPOs (Provention Bio and Immunocore). There are now a significant number of industry sponsored clinical trials ongoing in type 1 diabetes where we anticipate 10+ of the Fund's active portfolio companies entering the clinic for T1D within the next year or two.

In January 2025, Elizabeth Mily was appointed T1D Fund CEO after having most recently served as Executive Vice President, Strategy & Business Development, at Bristol Myers Squibb, and in senior roles at Barclays, Thermo Fisher Scientific, and Goldman Sachs. Under Miley's leadership, the Fund will execute an expansion of its current strategy focused on accelerating T1D cures by placing greater bets in promising companies and proactively engaging big pharma to grow the Fund's network and influence.



Breakthrough T1D is a Charity Navigator four-star charity, Platinum Level Guide Star participant, and a Better Business Bureau (BBB) Accredited Charity.